D. Blom

Most-cited papers

1. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

   D. Blom, T. Hála, M. Bolognese, M. Lillestol +12 more

   2014New England Journal of Medicine706 citations Open access

   Semantic Scholar

   Save

2. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.

   Aruna Das Pradhan, R. Glynn, J. Fruchart, Jean G. Macfadyen +32 more

   2022New England Journal of Medicine516 citations Open access

   Semantic Scholar

   Save

3. Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa

   Andrew Mary-Ann Hannah Muzzammil Erna Ziyanda Virginia Ha Boulle Davies Hussey Ismail Morden Vundle Zweigent, A. Boulle, M. Davies, H. Hussey +261 more

   2020Clinical Infectious Diseases377 citations Open access

   Semantic Scholar

   Save

4. Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa

   A. Boulle, M. Davies, H. Hussey, M. Ismail +46 more

   2020Clinical Infectious Diseases167 citations Open access

   Semantic Scholar

   Save

5. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma.

   D. Blom, G. Luyten, C. Mooy, S. Kerkvliet +2 more

   1997Investigative Ophthalmology and Visual Science111 citations

   Semantic Scholar

   Save

6. Proprotein convertase subtilisin/kexin type 9 inhibition

   D. Marais, D. Blom, F. Petrides, Y. Gouëffic +1 more

   2012Current Opinion in Lipidology59 citations

   Semantic Scholar

   Save

7. The approach study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS).

   D. Gaudet, A. Digenio, V. Alexander, M. Arca +12 more

   2017Atherosclerosis55 citations

   Semantic Scholar

   Save

8. HLA expression in a primary uveal melanoma, its cell line, and four of its metastases

   D. Blom, L. R. H. M. Schurmans, I. de Waard-siebinga, D. de Wolff-rouendaal +2 more

   1997British Journal of Ophthalmology47 citations Open access

   Semantic Scholar

   Save

9. Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

   J. Gibbs, S. Doshi, M. Kuchimanchi, A. Grover +6 more

   2016Journal of clinical pharmacology42 citations Open access

   Semantic Scholar

   Save

10. Effect of Evolocumab on Lipoprotein Particles.

    P. Toth, N. Sattar, D. Blom, S. Martin +6 more

    2017American Journal of Cardiology39 citations

    Semantic Scholar

    Save

11. Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus.

    N. Sattar, P. Toth, D. Blom, M. Koren +6 more

    2017American Journal of Cardiology36 citations

    Semantic Scholar

    Save

12. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.

    W. Goslings, D. Blom, I. de Waard-siebinga, E. van Beelen +3 more

    1996Investigative Ophthalmology and Visual Science35 citations

    Semantic Scholar

    Save

13. Acute Pancreatitis is Highly Prevalent and Complications can be Fatal in Patients with Familial Chylomicronemia: Results From a Survey of Lipidologist

    D. Gaudet, D. Blom, E. Bruckert, E. Stroes +8 more

    201630 citations

    Semantic Scholar

    Save

14. Effect of hyperthermia on expression of histocompatibility antigens and heat-shock protein molecules on three human ocular melanoma cell lines.

    D. Blom, I. de Waard-siebinga, R. Apte, G. Luyten +2 more

    1997Melanoma research30 citations

    Semantic Scholar

    Save

15. CEPHEUS SA: a South African survey on the under-treatment of hypercholesterolaemia

    F. J. Raal, C. Schamroth, D. Blom, Jan Marx +7 more

    2011Cardiovascular Journal of Africa26 citations Open access

    Semantic Scholar

    Save

16. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia—Brief Report

    A. Thedrez, B. Sjouke, Maxime Passard, Simon Prampart-Fauvet +15 more

    2016Arteriosclerosis, Thrombosis and Vascular Biology22 citations Open access

    Semantic Scholar

    Save

17. Multidrug resistance: related proteins in primary chorpoidal melanoma and in vitro cell lines

    P. PolvanderJ., D. Blom, M. Flens, Gre P. M.. Luyten +4 more

    199717 citations

    Semantic Scholar

    Save

18. Effects of transpupillary thermotherapy on immunological parameters and apoptosis in a case of primary uveal melanoma.

    L. R. Schurmans, D. Blom, I. de Waard-siebinga, J. Keunen +2 more

    1999Melanoma research16 citations

    Semantic Scholar

    Save

19. Abstract 16865: Safety and Tolerability of Very Low LDL-C Levels in Patients Treated with 52 Weeks of Evolocumab (AMG 145)

    M. Koren, D. Blom, R. Giugliano, E. Stroes +7 more

    20147 citations

    Semantic Scholar

    Save

20. Evaluation of the one-year efficacy, safety and glycaemic effects of evolocumab (AMG 145) in 4,802 subjects with, at high risk for, or at low risk for, diabetes mellitus

    Naveed Sattar, D. Preiss, D. Blom, C. Djedjos +5 more

    20156 citations

    Semantic Scholar

    Save

21. Evolocumab in hyperlipidemia.

    D. Blom, S. Wasserman, E. Stein

    2014New England Journal of Medicine6 citations

    Semantic Scholar

    Save

22. The APPROACH Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Volanesorsen Administered Subcutaneously to Patients with FCS

    D. Gaudet, A. Digenio, V. Alexander, M. Arca +11 more

    2018Atherosclerosis Supplements5 citations

    Semantic Scholar

    Save

23. LONG-TERM EVOLOCUMAB USE IN SUBJECTS WITH HOMOZYGOUS AND SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: PRIMARY RESULTS OF THE TAUSSIG TRIAL

    Raul D. Santos, G. Hovingh, D. Blom, H. Soran +6 more

    2019Journal of the American College of Cardiology3 citations Open access

    Semantic Scholar

    Save

24. Treatment with volanesorsen (VLN) reduced triglycerides and pancreatitis in patients with familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (sHTG) vs placebo: Results of the approach and compass studies

    D. Blom, S. Freedman, A. Gelrud, A. Digenio +9 more

    2018Pancreatology (Print)3 citations

    Semantic Scholar

    Save

25. Elevated triglycerides: A matter of the heart and pancreas

    D. Blom

    20183 citations Open access

    Semantic Scholar

    Save

26. EFFECTS OF EVOLOCUMAB (AMG 145) TREATMENT ON VITAMIN E LEVELS: RESULTS FROM THE 52-WEEK PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED DESCARTES STUDY

    D. Blom, M. Monsalvo, Kate Tsirtsonis, S. Wasserman +2 more

    20152 citations Open access

    Semantic Scholar

    Save

27. Dyslipidaemia in Type 2 diabetes : review

    D. Blom

    20132 citations

    Semantic Scholar

    Save

28. New therapeutic developments in lipidology

    D. Blom, A. Marais

    20092 citations

    Semantic Scholar

    Save

29. Familial Chylomicronemia Syndrome (FCS) Patients Recruited to the APPROACH Trial of Volanesorsen Therapy are Representative of Subjects with FCS

    D. Gaudet, D. Blom, E. Bruckert, E. Stroes +9 more

    20171 citations

    Semantic Scholar

    Save

30. Efficacy of one year of treatment with the PCSK9 inhibitor evolocumab (AMG 145) in 4,802 subjects with or without type 2 diabetes

    D. Preiss, N. Sattar, J. Robinson, C. Djedjos +5 more

    20151 citations

    Semantic Scholar

    Save

31. A report card for healthy aging in South Africa.

    D. Blom

    2022Cardiovascular Journal of Africa0 citations

    Semantic Scholar

    Save

32. Lomitapide in paediatric homozygous familial hypercholesterolemia – Real-world clinical experience from South Africa

    D. Blom

    2022Atherosclerosis0 citations Open access

    Semantic Scholar

    Save

33. IMPACT OF EVOLOCUMAB THERAPY IN PATIENTS WITH DISCORDANCE BETWEEN LDL-C AND LDL-P

    P. Toth, N. Sattar, D. Blom, S. Martin +5 more

    20170 citations Open access

    Semantic Scholar

    Save

34. Supplementary material : Effect of Evolocumab on Lipoprotein Particles

    P. Toth, N. Sattar, D. Blom, S. Martin +6 more

    20170 citations

    Semantic Scholar

    Save

35. SAFETY OF VERY LOW LDL-C LEVELS WITH EVOLOCUMAB: AN ANALYSIS OF 5942 PATIENTS FROM PHASE 2 AND 3 AND OPEN-LABEL EXTENSION STUDIES

    P. Toth, D. Blom, E. Stroes, C. Djedjos +8 more

    20160 citations Open access

    Semantic Scholar

    Save

36. Abstract 14506: Effect of Evolocumab on Lipoprotein Profiles in Patients With and Without Diabetes

    H. Soran, P. Toth, N. Sattar, D. Blom +8 more

    20160 citations

    Semantic Scholar

    Save

37. Effects of evolocumab (AMG 145) on vitamin e and serum adrenal and gonadal hormone levels; results from the 52-week, phase 3, double-blind, randomized, placebo-controlled descartes study

    D. Blom, C. Djedjos, Kate Tsirtsonis, S. Wasserman +2 more

    20150 citations

    Semantic Scholar

    Save

38. Acknowledgement to Referees

    J. Airaksinen, J. Amerena, Bruce D. Anderson, D. Angiolillo +14 more

    2015American Journal of Cardiovascular Drugs0 citations Open access

    Semantic Scholar

    Save

39. Abstract 17005: Effects of Evolocumab Treatment on Serum Adrenal and Gonadal Hormone Levels: Results from the 52-week, Phase 3, Double-blind, Randomized, Placebo-controlled DESCARTES Study

    D. Blom, C. Djedjos, Kate Tsirtsonis, S. Wasserman +2 more

    20140 citations

    Semantic Scholar

    Save

40. Cardiovascular protection in type 2 diabetes mellitus : more about... Best of 2010

    D. Blom

    20110 citations

    Semantic Scholar

    Save

41. LASSA Congress, Bloemfontein, April 2011

    D. Blom

    20110 citations Open access

    Semantic Scholar

    Save

42. Cardivascular protection in type 2 diabetes mellitus.

    D. Blom

    20110 citations

    Semantic Scholar

    Save

43. Cardiovascular protection in type 2 diabetes mellitus

    D. Blom

    20100 citations

    Semantic Scholar

    Save

44. More about... diabetes

    D. Blom

    20100 citations

    Semantic Scholar

    Save

45. have been many new and exciting developments in lipid- modifying therapy.

    D. Blom, Consultant Physician, D. Blom, D. Marais

    20090 citations

    Semantic Scholar

    Save

46. Physical signs in dyslipidaemia

    D. Blom

    20090 citations

    Semantic Scholar

    Save

47. Lipids are vital to life, but are important contributors to pathology.

    D. Blom, D. Blom

    20090 citations

    Semantic Scholar

    Save

48. Dyslipidaemia : guest editorial

    D. Blom

    20090 citations

    Semantic Scholar

    Save

49. New therapeutic developments in lipidology Since the previous CME on lipidology

    D. Blom

    20090 citations

    Semantic Scholar

    Save

50. Physical signs in dyslipidaemia : more about... dyslipidaemia

    D. Blom

    20090 citations

    Semantic Scholar

    Save